MarketCapExport financials
TELA Bio (TELA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
TELA Bio Income Statement 2025-2011 | TELA
Brief overview of financial results at TELA Bio
The comparison covers a five-year financial horizon. According to figures from TELA Bio, revenue changed from 18.2 million dollars to 80.3 million dollars over five years. The total change was +340.8%, with a CAGR of approximately 34.5%. This pace points to rapid expansion of the business.
The five-year change in gross profit reached +383.7%: from 11.2 million dollars to 54.3 million dollars. The cost base moved more slowly than the top line, which supported margins. Comparing the endpoints gives gross margins of 61.7% and 67.7%. The business retained more gross profit from each unit of revenue.
EBITDA changed from −$25.1 million to −$33.1 million (−32.2%). EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −137.6% to −41.3%. A wider margin confirms stronger operating efficiency.
Net income moved from −28.8 million dollars at the start to −38.8 million dollars at the end. Profitability deteriorated further over the five years.
Over the period, capitalization shifted from $185 million to $32.4 million (−82.5%). The valuation did not keep pace with the reported progress.
Overall conclusion
The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on sales growth, improving gross profitability and an improving EBITDA margin. The overall view is constrained by a narrow EBITDA buffer, declining capitalization and a weaker final result. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement TELA Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
32.4 M | 19.7 M | 131 M | 164 M | 177 M | 185 M | 26.1 M | - | - | - | - | - | - | - | - |
Shares |
46.9 M | 28.5 M | 22.9 M | 16.3 M | 14.5 M | 12.9 M | 1.77 M | - | - | - | - | - | - | - | - |
Historical Prices |
0.69 | 0.69 | 5.73 | 10.1 | 12.2 | 14.3 | 14.9 | - | - | - | - | - | - | - | - |
Net Income |
-38.8 M | -37.8 M | -46.7 M | -44.3 M | -33.3 M | -28.8 M | -22.4 M | -21.1 M | -21.3 M | - | - | - | - | - | - |
Revenue |
80.3 M | 69.3 M | 58.5 M | 41.4 M | 29.5 M | 18.2 M | 15.4 M | 8.27 M | 4.24 M | - | - | - | - | - | - |
Cost of Revenue |
25.6 M | 22.4 M | 18 M | 13.6 M | 10.3 M | 6.68 M | 5.87 M | 4.55 M | 1.71 M | - | - | - | - | - | - |
Gross Profit |
54.3 M | 46.5 M | 40.1 M | 27 M | 18.8 M | 11.2 M | 9.27 M | 2.94 M | 2.53 M | - | - | - | - | - | - |
Operating Income |
-33.8 M | -34.1 M | -44.1 M | -39 M | -29.5 M | -25.3 M | -19.2 M | -17.8 M | -16.9 M | - | - | - | - | - | - |
Interest Expense |
1.29 M | 1.42 M | 5.22 M | 4.05 M | 3.6 M | 3.56 M | 3.61 M | 1.8 M | 4.56 M | - | - | - | - | - | - |
EBITDA |
-33.1 M | -33.5 M | -43.6 M | -38.6 M | -29.2 M | -25.1 M | -18.6 M | -18.7 M | -16.2 M | - | - | - | - | - | - |
Operating Expenses |
88.1 M | 88.2 M | 84.2 M | 66.1 M | 48.3 M | 36.5 M | 28.4 M | 22.9 M | 19.5 M | - | - | - | - | - | - |
General and Administrative Expenses |
15.7 M | 14.7 M | 14.9 M | 13.9 M | 12.5 M | 10.1 M | 6.22 M | 4.9 M | 4.96 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement TELA Bio
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
45.4 M | 57.3 M | - | 45.4 M | 45.4 M | 45.3 M | 39.4 M | 24.7 M | 24.7 M | 24.6 M | 24.5 M | 24.5 M | 23.2 M | 19.2 M | 19.2 M | 16.8 M | 14.6 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.4 M | 14.4 M | 14.4 M | 11.4 M | 11.4 M | 11.4 M | 298 K | 296 K | 296 K | 296 K | 295 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.92 M | -12.3 M | - | -8.6 M | -9.92 M | -11.3 M | - | -10.4 M | -12.6 M | -5.66 M | - | -11 M | -10.8 M | -12 M | - | -10.7 M | -12.7 M | -10.9 M | - | -8.27 M | -8.26 M | -8.14 M | - | -7.7 M | -6.08 M | -7.22 M | - | -4.67 M | -5.26 M | -5.97 M | - | -2.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
20.2 M | 19.1 M | - | 20.7 M | 20.2 M | 18.5 M | - | 19 M | 16.1 M | 16.6 M | - | 15.1 M | 14.5 M | 11.9 M | - | 11.2 M | 10.4 M | 8.23 M | - | 7.65 M | 7.56 M | 5.88 M | - | 5.31 M | 3.51 M | 3.73 M | - | 3.97 M | 3.3 M | 3.31 M | - | 2.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
6 M | 6.44 M | - | 6.62 M | 6 M | 5.91 M | - | 6 M | 4.92 M | 5.17 M | - | 4.57 M | 4.2 M | 3.92 M | - | 3.74 M | 3.32 M | 3.16 M | - | 2.98 M | 2.4 M | 2.34 M | - | 1.95 M | 1.35 M | 1.45 M | - | 1.29 M | 1.32 M | 1.43 M | - | 769 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
14.1 M | 12.5 M | - | 14 M | 14.1 M | 12.5 M | - | 12.9 M | 11.1 M | 11.3 M | - | 10.4 M | 10.2 M | 7.9 M | - | 7.32 M | 6.55 M | 5 M | - | 4.6 M | 5.09 M | 3.46 M | - | 3.29 M | 2.08 M | 2.2 M | - | 2.6 M | 1.91 M | 1.8 M | - | 1.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.08 M | -10.5 M | - | -7.55 M | -9.08 M | -10.5 M | - | -9.36 M | -11.6 M | -4.83 M | - | -10.2 M | -10.4 M | -11.3 M | - | -9.49 M | -10.2 M | -9.84 M | - | -7.22 M | -7.31 M | -7.27 M | - | -6.86 M | -5.17 M | -6.5 M | - | -3.86 M | -4.3 M | -5.18 M | - | -2.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
379 K | 366 K | - | 152 K | 379 K | 479 K | - | 337 K | 301 K | 497 K | - | 558 K | 870 K | 1.25 M | - | 1.03 M | 934 K | 911 K | - | 922 K | 864 K | 889 K | - | 898 K | 884 K | 879 K | - | 899 K | 914 K | 912 K | - | 309 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-9.08 M | -10.4 M | - | - | - | -10.3 M | - | - | - | -4.69 M | - | - | - | -11.1 M | - | -9.22 M | -10.1 M | -9.77 M | - | -7.05 M | -7.19 M | -7.2 M | - | -6.7 M | -5.07 M | -6.44 M | - | -3.65 M | -4.16 M | -5.11 M | - | -2.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
23.2 M | 23 M | - | 21.5 M | 23.2 M | 23 M | - | 22.2 M | 22.6 M | 23.7 M | - | 20.6 M | 20.6 M | 19.2 M | - | 16.8 M | 16.8 M | 14.8 M | - | 11.8 M | 12.4 M | 10.7 M | - | 10.2 M | 7.25 M | 8.7 M | - | 6.46 M | 6.21 M | 6.98 M | - | 3.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.13 M | 4.17 M | - | 3.95 M | 4.13 M | 3.84 M | - | 3.68 M | 3.62 M | 3.83 M | - | 3.73 M | 3.47 M | 3.63 M | - | 3.53 M | 3.63 M | 3.46 M | - | 3.46 M | 2.97 M | 2.76 M | - | 2.61 M | 2.15 M | 2.52 M | - | 1.21 M | 1.2 M | 1.32 M | - | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company TELA Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |